Sunrest Lifescience (NSE:SUNREST) EBIT: ₹87.5 Mil (TTM As of Mar. 2026)


NSE:SUNREST Sunrest Lifescience Ltd NSE:SUNREST
41 GF Score
Price ₹35.05
! 5 Warning Signs
View Full Analysis

What is Sunrest Lifescience EBIT?

Sunrest Lifescience NSE:SUNREST 41 EBIT is ₹87.5 Mil as of Mar. 2026. GuruFocus rates NSE:SUNREST with a GF Score™ of 41/100. The stock has 5 warning signs investors should review.

Sunrest Lifescience's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹87.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹87.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunrest Lifescience's annualized ROC % for the quarter that ended in Mar. 2026 was 25.09%. Sunrest Lifescience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 46.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunrest Lifescience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 21.49%.

Sunrest Lifescience  (NSE:SUNREST) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunrest Lifescience's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=124.964 * ( 1 - 18.44% )/( (336.066 + 476.289)/ 2 )
=101.9206384/406.1775
=25.09 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=586.496 - 233.047 - ( 17.383 - max(0, 309.47 - 535.916+17.383))
=336.066

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=714.141 - 210.206 - ( 27.646 - max(0, 294.628 - 624.699+27.646))
=476.289

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunrest Lifescience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=175.092/( ( (43.81 + max(272.236, 0)) + (84.597 + max(357.437, 0)) )/ 2 )
=175.092/( ( 316.046 + 442.034 )/ 2 )
=175.092/379.04
=46.19 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(363.652 + 96.239 + 58.642) - (233.047 + 0 + 13.25)
=272.236

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(324.633 + 170.598 + 101.822) - (210.206 + 0 + 29.41)
=357.437

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunrest Lifescience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=87.546/407.452
=21.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunrest Lifescience EBIT Related Terms

Sunrest Lifescience EBIT Historical Data

* Premium members only.

The historical data trend for Sunrest Lifescience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunrest Lifescience EBIT Chart

Sunrest Lifescience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 10.74 28.03 8.11 29.29 115.22

Sunrest Lifescience Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only 16.10 -7.99 8.91 20.38 87.55

Sunrest Lifescience EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunrest Lifescience EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunrest Lifescience's EV-to-EBIT falls into.


NSE:SUNREST
41GF Score
Sunrest Lifescience Ltd NSE:SUNREST
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunrest Lifescience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹87.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹87.5 Mil mean?
Sunrest Lifescience (NSE:SUNREST) has a EBIT of ₹87.5 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunrest Lifescience.
Is Sunrest Lifescience's EBIT too high?
Sunrest Lifescience's current EBIT is ₹87.5 Mil. Overall, Sunrest Lifescience has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's EBIT compare to competitors?
Sunrest Lifescience's EBIT of ₹87.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunrest Lifescience. Sunrest Lifescience's current EBIT is ₹87.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current EBIT of ₹87.5 Mil. The current EBIT is ₹87.5 Mil. Sunrest Lifescience's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current EBIT is ₹87.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunrest Lifescience Business Description

Address YMCA Club, Near SG Highway, D-608 West Gate, Near Brooklin Tower, Makarba, Jivraj Park, Ahmedabad, GJ, IND, 380051
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
41GF Score

Get the complete analysis for NSE:SUNREST

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹35.05
Price